JoLLA: Tracking of Lipid Lowering Therapy in Jordan
Study Details
Study Description
Brief Summary
The present study aims to examine the clinical practice of modifying the dose of lipid-lowering therapy in patients with atherosclerotic cardiovascular disease (ASCVD), who have LDL-C > 70 mg/dl despite statin treatment.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
ASCVD is the leading cause of morbidity and mortality worldwide, in the Middle East and in Jordan. One of the major risk factors that contribute to the development and progression of ASCAD is dyslipidemia. A large number of clinical trials have reported the benefits of lowering LDL-C, in reducing the mortality rate among ASCAD patients.
The 2019 ACC/AHA blood cholesterol treatment guideline to reduce atherosclerotic cardiovascular risk in adults has expanded the role of LDL-C targets and reiterated the importance of achieving an LDL-C level of 70 mg/dl or less for patients who have ASCVD.
Patients on statins and other lipid-lowering therapy in Jordan have not been tracked in the past for the potential of up escalating the lipid-lowering therapy to reach the LDL-C target.
The investigation will enroll patients with ASCVD who have LAL-C >70 mg/dl on lipid-lowering therapy and follow them for 12 months to examine the treating physicians' action in up-titrating the lipid-lowering therapy dose(s) and the frequency of measuring serum lipids during the study period.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Patients with ASCVD Patients with ASCVD on statins and LDL-C more than 70 mg/dl |
Outcome Measures
Primary Outcome Measures
- Achieving a target LDL-C bloob level of 70 mg/dl or less [12 months]
At 1 year of follow up, all participants will have their blood lipid profile measured to examine the frequency of attaining an LDL-C level of 70 mg/dl or less
- Modifying the dose and class of lipid-lowering therapy [12 months]
Up titrating the dose of the same lipid-lowering agent or adding new agent during the study period of 12 months. Agents available include statins, ezetimibe and PCSK9 inhibitors.
- Clinical cardiovascular events [12 months]
The study will study the frequency of incident acute cardiovascular the participating individuals experienced. Such events include cardiovascular death, acute coronary syndrome, stroke, lower extremity acute arterial insufficiency, and arterial revascularization procedure (coronary and other arterial beds).
Eligibility Criteria
Criteria
Inclusion criteria
-
Adults aged 18 years or old.
-
Presence of atherosclerotic cardiovascular disease on lipid-lowering therapy.
-
LDL-C > 70mg/dl.
-
Willingness to sign an informed consent.
Exclusion criteria
-
Life-threatening disease with limited survival.
-
Unwillingness to sign an informed consent.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Istishari Hospital | Amman | Jordan | 11184 | |
| 2 | Abdali Hospital | Amman | Jordan |
Sponsors and Collaborators
- Jordan Collaborating Cardiology Group
Investigators
- Principal Investigator: Ayman Hammoudeh, MD FACC, Istishari Hospital, Amman, Jordan
Study Documents (Full-Text)
More Information
Publications
None provided.- JCCG.JoLLA.10.2022